{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:38:09Z","timestamp":1777934289105,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T00:00:00Z","timestamp":1503273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>Directed immunotherapy at the programmed cell death-1 receptor has demonstrated efficacy in non-small-cell lung cancer, metastatic melanoma, and various other malignancies. Immune checkpoint inhibitors are innovative therapies producing some impressive clinical responses with a more manageable adverse effect profile when compared to traditional chemotherapy. The more common adverse effects associated with these agents include fatigue, rash, myalgia, pyrexia, and cough, but less common yet serious adverse effects have included immune-mediated colitis, pneumonitis, hepatitis, type 1 diabetes, and encephalitis. Here we present a case of a female patient with glioblastoma multiforme, who was treated with the programmed cell death-1 receptor inhibitor nivolumab and subsequently developed aplastic anemia.<\/jats:p>","DOI":"10.1177\/1078155217726159","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T05:30:59Z","timestamp":1503293459000},"page":"221-225","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":33,"title":["Nivolumab-induced aplastic anemia: A case report and literature review"],"prefix":"10.1177","volume":"25","author":[{"given":"Rachel R","family":"Comito","sequence":"first","affiliation":[{"name":"Hartford Hospital, Hartford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynette A","family":"Badu","sequence":"additional","affiliation":[{"name":"Hartford Hospital, Hartford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Forcello","sequence":"additional","affiliation":[{"name":"Smilow Cancer Hospital at Yale New Haven, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,8,21]]},"reference":[{"key":"bibr1-1078155217726159","unstructured":"American Brain Tumor Association. Glioblastoma (GBM). 2014. Available at: http:\/\/www.abta.org\/brain-tumor-information\/types-of-tumors\/glioblastoma.html (accessed 3 January 2017)."},{"key":"bibr2-1078155217726159","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-016-2299-2"},{"key":"bibr3-1078155217726159","unstructured":"National Cancer Institute. With immunotherapy, glimmers of progress against glioblastoma. 2016.Available at: http:\/\/www.cancer.gov\/types\/brain\/research\/ immunotherapy-glioblastoma (accessed 3 January 2017)."},{"key":"bibr4-1078155217726159","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov071"},{"key":"bibr5-1078155217726159","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.2014"},{"key":"bibr6-1078155217726159","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox036.044"},{"key":"bibr7-1078155217726159","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now212.069"},{"key":"bibr8-1078155217726159","unstructured":"OPDIVO (nivolumab) (package insert). Princeton, NJ: Bristol-Myers Squibb Company, 2014."},{"key":"bibr9-1078155217726159","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"key":"bibr10-1078155217726159","unstructured":"Food and Drug Administration. Gleostine (Lomustine) capsules. Available at: http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/ucm485677.htm (accessed 6 January 2017)."},{"key":"bibr11-1078155217726159","unstructured":"Gerson SL, Bulgar AD, Weeks LD, et\u00a0al. Classical alkylating agents. In: Chabner BA and Longo DL (eds)\n                      Cancer chemotherapy and biotherapy: principles and practice\n                      . 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2011."},{"key":"bibr12-1078155217726159","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1510079"},{"key":"bibr13-1078155217726159","unstructured":"US National Library of Medicine. Adverse drug reaction probability scale (Naranjo) in drug induced liver.\n                      Livertox\n                      . Available at: https:\/\/livertox.nih.gov\/Narajo.html (accessed 23 June 2017)."},{"key":"bibr14-1078155217726159","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051"},{"key":"bibr15-1078155217726159","doi-asserted-by":"publisher","DOI":"10.1159\/000452296"},{"key":"bibr16-1078155217726159","doi-asserted-by":"publisher","DOI":"10.1159\/000447508"},{"key":"bibr17-1078155217726159","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00242"},{"key":"bibr18-1078155217726159","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.2010"},{"key":"bibr19-1078155217726159","unstructured":"University of Virginia. Stereotactic radiosurgery with nivolumab and valproate in patients with recurrent glioblastoma. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02648633 (accessed 3 January 2017)."},{"key":"bibr20-1078155217726159","unstructured":"Olivia Newton-John Cancer Research Institute. A phase II trial of ipilimumab and nivolumab for the treatment of rare cancers. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02923934?term=nivolumab&rank=18 (accessed 5 January 2017)."},{"key":"bibr21-1078155217726159","unstructured":"Bristol-Meyers, S. Bristol-Myers Squibb announces results from CheckMate -143, a phase 3 study of Opdivo (nivolumab) in patients with glioblastoma multiforme. Available at: https:\/\/news.bms.com\/press-release\/bmy\/bristol-myers-squibb-announces-results-checkmate-143-phase-3-study-opdivo-nivoluma (accessed 7 August 2017)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217726159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155217726159","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217726159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:17:36Z","timestamp":1777688256000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155217726159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,21]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1177\/1078155217726159"],"URL":"https:\/\/doi.org\/10.1177\/1078155217726159","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,21]]}}}